Safety of Lumiracoxib in Patients With Osteoarthritis

• Status: Completed
• Trial end date: 2001-03-01
• Target enrollment: 0
• Participant gender: All

Summary

This safety study evaluated the incidence of gastrointestinal adverse events and edema in patients with osteoarthritis treated with lumiracoxib and rofecoxib as comparator

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novartis
• Treatments: Diclofenac; Lumiracoxib; Rofecoxib

Criteria

Inclusion Criteria:

• Age >=50 years old

• Primary osteoarthritis in hip, hand, knee or spine for at least 3 month

• Pain in the target joint of moderate intensity

• Written informed consent

Exclusion Criteria:

• Secondary osteoarthritis

• Active upper gastro intestinal tract ulceration

• Inflammatory joint disease

• Gout

• Clinically significant hepatic or renal disease

Other in and exclusion criteria may apply